You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsosorbide Dinitrate
Accession NumberDB00883  (APRD00455)
TypeSmall Molecule
GroupsApproved
DescriptionA vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. [PubChem]
Structure
Thumb
Synonyms
1,4:3,6-Dianhydrosorbitol 2,5-dinitrate
Carvasin
Cedocard retard
D-Isosorbide dinitrate
Dianhydrosorbitol 2,5-dinitrate
Dinitrate d'isosorbide
Dinitrato de isosorbida
Dinitroisosorbide
Dinitrosorbide
Flindix
ISDN
Isoket
Isorbid
Isordil
Isosorbide 2,5-dinitrate
Isosorbide dinitrate
Isosorbidi dinitras
Nitrosorbide
Sorbide nitrate
Sorbidilat
Sorbidnitrate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cedocard-SR Srt 20mgTablet, extended release20 mgOralPaladin Labs Inc1987-12-312009-08-07Canada
Cedocard-SR Srt 40mgTablet, extended release40 mgOralPaladin Labs Inc1995-12-312009-08-07Canada
Coradur Tab 20mgTablet, extended release20 mgOralGlaxo Canada Inc1987-12-311997-04-25Canada
CoronexTablet10 mgOralWyeth Canada1994-12-312007-01-08Canada
CoronexTablet30 mgOralWyeth Canada1994-12-312007-01-08Canada
Coronex 5mg Sublingual TabletsTablet5 mgSublingualWyeth Canada1994-12-312007-01-08Canada
Dilatrate SRCapsule40 mg/1OralAuxilium Pharmaceuticals, Inc.2014-10-242015-12-29Us
Dilatrate SRCapsule, extended release40 mg/1OralEndo Pharmaceuticals, Inc.2012-02-15Not applicableUs
IsdnTablet10 mgOralAa Pharma Inc1982-12-31Not applicableCanada
IsdnTablet30 mgOralAa Pharma Inc1982-12-31Not applicableCanada
IsdnTablet5 mgSublingualAa Pharma Inc1985-12-31Not applicableCanada
Isordil 10 Titradose Tab 10mgTablet10 mgOralWyeth Ltd.1960-12-311997-08-14Canada
Isordil 10 Titradose Tablets 10mgTablet10 mgOralWyeth Ayerst Canada Inc.1994-12-312002-06-10Canada
Isordil 30 Titradose Tab 30mgTablet30 mgOralWyeth Ltd.1974-12-311996-09-10Canada
Isordil 30 Titradose Tablets 30mgTablet30 mgOralWyeth Ayerst Canada Inc.1994-12-312001-08-30Canada
Isordil Sublingual Tab 5mgTablet5 mgSublingualWyeth Ltd.1967-12-311997-08-14Canada
Isordil Sublingual Tablets 5mgTablet5 mgSublingualWyeth Ayerst Canada Inc.1996-11-252001-08-30Canada
Isordil TitradoseTablet5 mg/1OralValeant Pharmaceuticals North America LLC2013-04-01Not applicableUs
Isordil TitradoseTablet40 mg/1OralValeant Pharmaceuticals North America LLC2013-04-01Not applicableUs
Isordil TitradoseTablet40 mg/1OralAmerican Health Packaging2012-02-132015-12-29Us
Isordil TitradoseTablet5 mg/1OralBTA Pharmaceuticals, Inc.2009-10-01Not applicableUs
Isordil TitradoseTablet40 mg/1OralBTA Pharmaceuticals, Inc.2009-10-012015-10-31Us
Isosorbide 10 Tab 10mgTablet10 mgOralPro Doc Limitee1983-12-312010-07-13Canada
Isosorbide 30 Tab 30mgTablet30 mgOralPro Doc Limitee1983-12-312010-07-13Canada
Isosorbide Tab 30mgTablet30 mgOralPharmascience Inc1990-12-31Not applicableCanada
Isosorbide-5 Tab 5mgTablet5 mgSublingualPro Doc Limitee1986-12-312010-07-13Canada
Novo-sorbide Tab 10mgTablet10 mgOralNovopharm Limited1983-12-312012-10-22Canada
Novo-sorbide Tab 30mgTablet30 mgOralNovopharm Limited1983-12-312012-10-22Canada
Nu-isdn TabletsTablet30 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-isdn TabletsTablet5 mgSublingualNu Pharm IncNot applicableNot applicableCanada
Nu-isdn TabletsTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-isosorbide Tab 10mgTablet10 mgOralPharmascience Inc1990-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IsosorbideTablet20 mg/1OralGolden State Medical Supply, Inc.1987-11-02Not applicableUs
IsosorbideTablet10 mg/1OralMc Kesson Contract Packaging2011-09-22Not applicableUs
IsosorbideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
IsosorbideTablet20 mg/1OralHikma Pharmaceutical1983-04-26Not applicableUs
IsosorbideTablet5 mg/1OralGolden State Medical Supply, Inc.1987-10-26Not applicableUs
IsosorbideTablet20 mg/1OralMc Kesson Contract Packaging2011-11-04Not applicableUs
IsosorbideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
IsosorbideTablet5 mg/1OralHikma Pharmaceutical1978-12-01Not applicableUs
IsosorbideTablet30 mg/1OralGolden State Medical Supply, Inc.2007-01-10Not applicableUs
IsosorbideTablet10 mg/1OralCardinal Health1987-10-292015-12-29Us
IsosorbideTablet10 mg/1OralGolden State Medical Supply, Inc.1987-10-26Not applicableUs
IsosorbideTablet20 mg/1OralCardinal Health1987-10-292015-12-29Us
IsosorbideTablet10 mg/1OralHikma Pharmaceutical1978-12-01Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-04-26Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralPar Pharmaceutical Inc.1979-12-22Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralWest Ward Pharmaceuticals Corp1983-04-26Not applicableUs
Isosorbide DinitrateTablet2.5 mg/1SublingualWest ward Pharmaceutical Corp1978-12-01Not applicableUs
Isosorbide DinitrateTablet, extended release40 mg/1OralPhysicians Total Care, Inc.1995-01-18Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Isosorbide DinitrateTablet10 mg/1Oralbryant ranch prepack1978-12-01Not applicableUs
Isosorbide DinitrateTablet30 mg/1OralAv Kare, Inc.2016-06-07Not applicableUs
Isosorbide DinitrateTablet30 mg/1OralCarilion Materials Management1983-02-10Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralBlue Point Laboratories2014-02-06Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralSandoz Inc1988-01-07Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralREMEDYREPACK INC.2011-10-19Not applicableUs
Isosorbide DinitrateTablet, extended release40 mg/1OralCore Pharma, Llc2008-04-022016-03-16Us
Isosorbide DinitrateTablet20 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1981-12-15Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralAv Pak2016-09-13Not applicableUs
Isosorbide DinitrateTablet, extended release40 mg/1OralKAISER FOUNDATION HOSPITALS2011-03-15Not applicableUs
Isosorbide DinitrateTablet30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-02-10Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralPar Pharmaceutical Inc.1981-12-15Not applicableUs
Isosorbide DinitrateTablet30 mg/1OralCarilion Materials Management1983-02-10Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralCardinal Health1988-01-07Not applicableUs
Isosorbide DinitrateTablet5 mg/1SublingualWest ward Pharmaceutical Corp1978-12-01Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralCardinal Health1988-01-07Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralMajor Pharmaceuticals1988-01-07Not applicableUs
Isosorbide DinitrateTablet5 mg/1Oralbryant ranch prepack1978-12-01Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-09-04Not applicableUs
Isosorbide DinitrateTablet, extended release40 mg/1OralCarilion Materials Management2009-09-22Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralBlue Point Laboratories2014-02-06Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralSandoz Inc1988-01-07Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralGolden State Medical Supply, Inc.2015-09-04Not applicableUs
Isosorbide DinitrateTablet30 mg/1OralPar Pharmaceutical Inc.1983-02-10Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralAmerican Health Packaging2013-10-15Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralWest Ward Pharmaceuticals Corp1978-12-01Not applicableUs
Isosorbide DinitrateTablet, extended release40 mg/1OralKAISER FOUNDATION HOSPITALS2011-10-31Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-07Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralREMEDYREPACK INC.2012-12-27Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralCarilion Materials Management1978-12-01Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralCardinal Health1988-04-07Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-09-04Not applicableUs
Isosorbide DinitrateTablet, extended release40 mg/1OralCaraco Pharmaceutical Laboratories Ltd.2009-09-22Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralMajor Pharmaceuticals1988-04-07Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1981-12-152016-01-27Us
Isosorbide DinitrateTablet10 mg/1OralGolden State Medical Supply, Inc.2015-09-04Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralAvera Mc Kennan Hospital2015-10-02Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralBlue Point Laboratories2014-02-06Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralSandoz Inc1988-04-07Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralPar Pharmaceutical Inc.1979-12-13Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralAmerican Health Packaging2013-10-15Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralWest Ward Pharmaceuticals Corp1978-12-01Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1978-12-01Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralCarilion Materials Management1978-12-01Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralCardinal Health2013-10-15Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-04-07Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralREMEDYREPACK INC.2014-03-252016-10-13Us
Isosorbide DinitrateTablet10 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1979-12-22Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralAv Pak2016-09-13Not applicableUs
Isosorbide DinitrateTablet, extended release40 mg/1OralKAISER FOUNDATION HOSPITALS2010-03-25Not applicableUs
Isosorbide DinitrateTablet5 mg/1OralREMEDYREPACK INC.2011-03-10Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralGolden State Medical Supply, Inc.2015-09-04Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralA S Medication Solutions Llc1988-04-07Not applicableUs
Isosorbide DinitrateTablet20 mg/1OralAvera Mc Kennan Hospital2015-04-15Not applicableUs
Isosorbide DinitrateTablet10 mg/1OralREMEDYREPACK INC.2016-03-11Not applicableUs
Isosorbide SublingualTablet5 mg/1SublingualGolden State Medical Supply, Inc.1987-11-02Not applicableUs
Isosorbide SublingualTablet2.5 mg/1SublingualGolden State Medical Supply, Inc.1978-12-01Not applicableUs
Isosorrbide DinitrateTablet30 mg/1OralWest ward Pharmaceutical Corp2007-01-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CarvasinAyerst
Dilatrate-SRSchwarz
FlindixVitória
IsoketSchwarz
IsorbidArmstrong
IsordilValeant
NitrosorbideLusofarmaco
SorbidilatActavis
Brand mixtures
NameLabellerIngredients
BidilArbor Pharmaceuticals
SaltsNot Available
Categories
UNIIIA7306519N
CAS number87-33-2
WeightAverage: 236.1363
Monoisotopic: 236.028065242
Chemical FormulaC6H8N2O8
InChI KeyMOYKHGMNXAOIAT-JGWLITMVSA-N
InChI
InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
IUPAC Name
(3S,3aS,6R,6aS)-6-(nitrooxy)-hexahydrofuro[3,2-b]furan-3-yl nitrate
SMILES
[H][C@]12OC[[email protected]](O[N+]([O-])=O)[C@@]1([H])OC[[email protected]]2O[N+]([O-])=O
Pharmacology
IndicationFor the prevention of angina pectoris due to coronary artery disease.
Structured Indications
PharmacodynamicsIsosorbide Dinitrate is a moderate to long acting oral organic nitrate used for the relief and prophylactic management of angina pectoris. It relaxes the vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end- diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure.
Mechanism of actionSimilar to other nitrites and organic nitrates, isosorbide dinitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Atrial natriuretic peptide receptor 1Proteinyes
agonist
HumanP16066 details
Related Articles
AbsorptionAbsorption of isosorbide dinitrate after oral dosing is nearly complete, but bioavailability is highly variable (10% to 90%), with extensive first-pass metabolism in the liver. The average bioavailability of isosorbide dinitrate is about 25%.
Volume of distribution
  • 2 to 4 L/kg
Protein bindingVery low
Metabolism

Hepatic

Route of eliminationNot Available
Half life1 hour
ClearanceNot Available
ToxicitySymptoms of overdose include reduced cardiac output and hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.Approved
AliskirenThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Isosorbide Dinitrate.Approved
AmiodaroneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Dinitrate.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Arsenic trioxide.Approved, Investigational
AtazanavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Dinitrate.Approved
AtomoxetineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atomoxetine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Isosorbide Dinitrate.Experimental
BarbitalBarbital may increase the hypotensive activities of Isosorbide Dinitrate.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Dinitrate.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Dinitrate.Approved
BepridilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Dinitrate.Approved
BexaroteneThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Dinitrate.Approved
BoceprevirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Dinitrate.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bupivacaine.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Isosorbide Dinitrate.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Captopril.Approved
CarbamazepineThe metabolism of Isosorbide Dinitrate can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Dinitrate.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Carvedilol.Approved, Investigational
CeritinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ceritinib.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Dinitrate.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilnidipine.Approved
ClarithromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Dinitrate.Approved
ClotrimazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clozapine.Approved
CobicistatThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Dinitrate.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Dinitrate.Approved, Investigational
DarunavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Desflurane.Approved
DexamethasoneThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Dinitrate.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Diclofenamide.Approved
DihydroergotamineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Isosorbide Dinitrate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Dinitrate.Approved
DoxycyclineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dronedarone.Approved
DuloxetineIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfavirenzThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Dinitrate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide Dinitrate.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Dinitrate.Approved
ErythromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Dinitrate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Etacrynic acid.Approved
EthanolEthanol may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
EtravirineThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Etravirine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Fimasartan.Approved
FluconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.Approved
FosphenytoinThe metabolism of Isosorbide Dinitrate can be increased when combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Dinitrate.Approved, Vet Approved
Fusidic AcidThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Fusidic Acid.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
HydralazineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydroflumethiazide.Approved
IdelalisibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Dinitrate.Approved
IndinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Isosorbide Dinitrate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isoflurane.Approved, Vet Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Dinitrate.Approved
ItraconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Dinitrate.Approved
LacidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Levobupivacaine.Approved
LevodopaIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.Approved
LovastatinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Isosorbide Dinitrate can be increased when combined with Lumacaftor.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Dinitrate.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Isosorbide Dinitrate.Approved
MethohexitalMethohexital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
MetipranololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Dinitrate.Approved, Investigational
MifepristoneThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Dinitrate.Approved
MitotaneThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Dinitrate.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Isosorbide Dinitrate.Approved
MorphineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nadolol.Approved
NafcillinThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Nafcillin.Approved
NebivololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Isosorbide Dinitrate can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Dinitrate.Approved
NicorandilNicorandil may increase the hypotensive activities of Isosorbide Dinitrate.Approved
NifedipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nifedipine.Approved
NilotinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Dinitrate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Dinitrate.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isosorbide Dinitrate.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Dinitrate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Obinutuzumab.Approved
OlaparibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Dinitrate.Approved, Investigational
OsimertinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Osimertinib.Approved
OxprenololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Papaverine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Isosorbide Dinitrate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Dinitrate.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Isosorbide Dinitrate can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Phentolamine.Approved
PhenytoinThe metabolism of Isosorbide Dinitrate can be increased when combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pipamperone.Approved
PosaconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Dinitrate.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Prilocaine.Approved
PrimidoneThe metabolism of Isosorbide Dinitrate can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Dinitrate.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Dinitrate.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Dinitrate.Approved
RanolazineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Dinitrate.Approved
RifabutinThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifapentine.Approved
RiociguatIsosorbide Dinitrate may increase the hypotensive activities of Riociguat.Approved
RisperidoneIsosorbide Dinitrate may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ritonavir.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Ropivacaine.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sacubitril.Approved
SaquinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved, Investigational
SiltuximabThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Dinitrate.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Dinitrate.Approved
St. John's WortThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tamsulosin.Approved, Investigational
TelaprevirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Thioridazine.Approved
TiclopidineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Isosorbide Dinitrate.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Dinitrate.Approved
TocilizumabThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Dinitrate.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Dinitrate.Approved
UdenafilUdenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Dinitrate.Approved, Investigational
VardenafilVardenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
VenlafaxineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Dinitrate.Approved
VoriconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take without regard to meals. Absorption is faster on an empty stomach.
References
Synthesis Reference

Gunter Cordes, Ulrich Munch, Ewald Giesselmann, “Supersaturated isosorbide dinitrate solution, process for its production and its use.” U.S. Patent US4156736, issued August, 1976.

US4156736
General ReferencesNot Available
External Links
ATC CodesC05AE02C01DA58C01DA08
AHFS Codes
  • 24:12.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.935
Blood Brain Barrier+0.9559
Caco-2 permeable-0.5746
P-glycoprotein substrateNon-substrate0.8064
P-glycoprotein inhibitor INon-inhibitor0.6173
P-glycoprotein inhibitor IINon-inhibitor0.8911
Renal organic cation transporterNon-inhibitor0.8453
CYP450 2C9 substrateNon-substrate0.9057
CYP450 2D6 substrateNon-substrate0.9021
CYP450 3A4 substrateSubstrate0.5298
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9534
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9538
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7116
BiodegradationReady biodegradable0.7633
Rat acute toxicity2.4849 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5057
hERG inhibition (predictor II)Non-inhibitor0.9381
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
  • Schwarz pharma inc
  • Wyeth ayerst laboratories
  • Astrazeneca pharmaceuticals lp
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Biovail laboratories inc
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Superpharm corp
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • West ward inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral40 mg
CapsuleOral40 mg/1
Capsule, extended releaseOral40 mg/1
TabletSublingual5 mg
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral10 mg/1
TabletOral20 mg/1
TabletSublingual2.5 mg/1
TabletSublingual5 mg/1
Tablet, extended releaseOral40 mg/1
TabletOral30 mg
TabletOral30 mg/1
TabletOral10 mg
Prices
Unit descriptionCostUnit
Isordil Titradose 40 mg tablet1.7USD tablet
Isordil 40 mg tablet1.58USD tablet
Dilatrate-sr 40 mg capsule1.48USD capsule
Isochron 40 mg tablet sa1.07USD tablet
Isosorbide Dinitrate CR 40 mg Controlled Release Tabs0.88USD tab
Isosorbide Mononitrate 20 mg tablet0.78USD tablet
Isosorbide Mononitrate 10 mg tablet0.74USD tablet
Isordil Titradose 5 mg tablet0.68USD tablet
Isordil 5 mg tablet0.65USD tablet
Isosorbide dn 30 mg tablet0.53USD tablet
Isordil 10 mg tablet0.5USD tablet
Isosorbide Dinitrate 30 mg tablet0.5USD tablet
Cedocard-Sr 20 mg Sustained-Release Tablet0.44USD tablet
Isosorbide Dinitrate 10 mg tablet0.43USD tablet
Isosorbide Dinitrate 20 mg tablet0.43USD tablet
Isosorbide Dinitrate 2.5 mg Sublingual Tabs0.39USD tab
Isosorbide Dinitrate 5 mg Sublingual Tabs0.21USD tab
Isosorbide dn 2.5 mg tablet sl0.21USD tablet
Isosorbide dn 5 mg tablet sl0.21USD tablet
Isosorbide dn 20 mg tablet0.2USD tablet
Isosorbide Dinitrate 5 mg tablet0.17USD tablet
Isosorbide dn 10 mg tablet0.17USD tablet
Isosorbide dn 5 mg tablet0.17USD tablet
Apo-Isdn 30 mg Tablet0.09USD tablet
Apo-Isdn 5 mg Sublingual Tablet0.07USD tablet
Apo-Isdn 10 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6465463 No2000-09-082020-09-08Us
US6784177 No2000-09-082020-09-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point70 °CPhysProp
water solubility550 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.31HANSCH,C ET AL. (1995)
logS-2.63ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.938 mg/mLALOGPS
logP0.87ALOGPS
logP0.44ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area128.56 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity44.77 m3·mol-1ChemAxon
Polarizability18.07 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassFurofurans
Sub ClassIsosorbides
Direct ParentIsosorbides
Alternative Parents
Substituents
  • Isosorbide
  • Alkyl nitrate
  • Oxolane
  • Organic nitrate
  • Nitrate ester
  • Organic nitro compound
  • Organic nitric acid or derivatives
  • Oxacycle
  • Organic 1,3-dipolar compound
  • Allyl-type 1,3-dipolar organic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organic zwitterion
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein kinase activity
Specific Function:
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
Gene Name:
NPR1
Uniprot ID:
P16066
Molecular Weight:
118918.11 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Villarroya M, Lopez MG, de Pascual R, Garcia AG: Preclinical profile of PF9404C, a nitric oxide donor with beta receptor blocking properties. Cardiovasc Drug Rev. 2005 Summer;23(2):149-60. [PubMed:16007231 ]
  4. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu K, Takabayashi A, Adachi T, Semenza GL, Fukuda K: The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. Biochem Biophys Res Commun. 2004 Nov 5;324(1):417-23. [PubMed:15465035 ]
  5. Beauregard C, Brandt PC, Chiou GC: Nitric oxide and cyclic GMP-mediated protein secretion from cultured lacrimal gland acinar cells. J Ocul Pharmacol Ther. 2002 Oct;18(5):429-43. [PubMed:12419094 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:37